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Abstract: The COVID-19 pandemic has created major insecurities regarding whether we can and should
maintain the current standards of diagnosis and treatment and access to care for patients with cancer.
This is particularly true in the field of neuro-oncology, where the perceived benefit of therapeutic interven-
tions is often low, although this notion is partially incorrect. We acknowledge that the recommendations
for care of patients with cancer have become a moving target and that all recommendations are subject
to modification based on national and institutional regulations. Still, some important considerations
and proposals may apply broadly. First, it is important to note that old age and cardiovascular and
pulmonary co-morbidities are the major risk factors for experiencing a severe course of and for dying of
COVID-19, not chronic immunosuppression and cancer. Second, many of the considerations on how we
should adapt clinical practice in neuro-oncology in view of COVID-19 that are now dominating discus-
sions at local tumour boards, as well as on the institutional level and within societies of neuro-oncology,
are not novel but have been valid before and only now have become a priority. More than ever, it seems
to be mandatory to adhere to evidence-based medicine and not to prescribe potentially toxic, notably
immunsuppresssive systemic therapy where evidence for efficacy is low. Furthermore, it is more obvious
now that oncologists must not miss the right time for advance care planning, that is, supporting patients
in understanding and sharing their personal values, life goals and preferences regarding future medical
care. The major psychological impact of transforming oncology care to teleconferences and videocon-
ferences and of the important strict recommendation of social distancing must not be overlooked in a
patient population that is characterised by significant prevalence of cognitive decline and by the general
perception that their life span may not exceed the life span of the COVID-19 pandemic.
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The COVID-19 pandemic has created major insecurities regarding whether we can 
and whether we should maintain the current standards of diagnosis and treatment 
and access to care for patients with cancer. This is particularly true in the field of 
Neuro-oncology where the perceived benefit of therapeutic interventions is often low, 
although this notion is partially incorrect. We acknowledge that recommendations for 
care of cancer patients have become a moving target and that all recommendations 
are subject to modification based on national and institutional regulations. Still, some 
important considerations and proposals may apply broadly. First, it is important to 
note that old age and cardiovascular and pulmonary comorbidities are the major risk 
factors for experiencing a severe course of and for dying of COVID-19, not chronic 
immunosuppression and not cancer. Second, many of the considerations on how we 
should adapt clinical practice in Neuro-Oncology in view of COVID-19that are now 
dominating discussions at local tumor boards as well as on institutional level and 
within societies of Neuro-oncology, are not novel, but have been valid before and 
only now become a priority. More than ever, it seems to be mandatory to adhere to 
evidence-based medicine, and not to prescribe potentially toxic, notably 
immunsuppresssive systemic therapy where evidence for efficacy is low. 
Furthermore, it is more obvious now that oncologists must not miss the right time for 
advance care planning, i.e. supporting patients in understanding and sharing their 
personal values, life goals, and preferences regarding future medical care. The major 
psychological impact of transforming oncology care to teleconferences and 
videoconferences and of the important strict recommendation of social distancing 
must not be overlooked in a patient population that is characterized by significant 
prevalence of cognitive decline and by the general perception that their lifespan may 
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The coronavirus disease (COVID)-19 epidemic has changed the way medicine is 
practiced almost throughout the world. Age has emerged as the most impressive risk 
factor of succumbing to COVID-19. Among the large population of elderly patients 
who are treated for COVID-19, there is a strong prevalence of cardiovascular and 
pulmonary comorbidity, which suggests that frailty rather than age confers 
susceptibility to COVID-19. Thus the consideration that no resources should be 
invested into the elderly per se, e.g. by withholding admission to intensive care units 
for COVID-19 patients beyond a certain age, is therefore not only ethically 
questionable, but also scientifically false. Further, in contrast to what might be 
expected, chronic immunosuppression and cancer do not seem to be major 
predictors of COVID-19 vulnerability, although few data are available on this topic so 
far. Limited reports on COVID-19 and cancer which stem from China indicate that the 
disease course of COVID-19 may be more severe in cancer patients, but do not 
allow to definitely conclude that cancer as such increases the risk of COVID-19 
(Zhang), however likely this may seem. Among 1524 cancer patients from a single 
institution in Wuhan, 12 patients (0.79%) has SARS-CoV-2 infection, which was 
higher than the cumulative incidence of 0.37% of COVID-19 cases in the respective 
general population (Yu). However, it is inappropriate to conclude that patients seen at 
a cancer center share the same risk factors of cardiopulmonary comorbidity and age 
as the general population. In a survey of 2007 COVID-19 cases from 575 hospitals in 
China, 18 patients had cancer (Liang), a figure that we do not interprete as evidence 
for strong associations between COVID-19 and cancer. The most common diagnosis 
was lung cancer (5 of 18 patients, 28%) and three quarter of the patients (12 of 18) 
were not undergoing active anti-cancer therapy, but were cancer survivors in routine 
follow-up. The authors stress that the rate of cancer among their COVID-19 patients 
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exceeds that of the general population, but without controlling for age and 
comorbidity, therefore, such figures need to be interpreted with caution. 
Accordingly, we need to make sure that we as health care providers stay informed 
and that we provide sufficient information to patients and caregivers on the relative 
risks and benefits of all interventions including anti-tumor treatments and supportive 
care. We need to outline that teleconferences and videoconsulting are valid 
alternatives, although hopefully a transient measure only. There is a priori no 
evidence to suggest that coming to an outpatient visit to hospital is more dangerous 
than going to visit relatives or for shopping. It is important to outline that it is not the 
hospital per se, but the number of other people encountered on the journey and the 
vigor with which social distancing is maintained that likely determines risk of infection. 
We must avoid inferior outcome of our patients simply because these are too afraid 
to come to hospital when in fact they should. Finally, we also need to make sure that 
we maintain the specialized Neuro-Oncology workforce at our institutions, e.g., by 
reorganizing multidisciplinary tumor boards to remote conferences or conferences 
with one decision maker per discipline only. 
 
Considerations that are not new, but become more prominent during the COVID-19 
pandemic 
It is a common theme in Neuro-Oncology that therapeutic interventions for which 
there is no evidence should not routinely be offered to patients. It just seems to be so 
much easier for many health care providers and also caregivers to recommend 
specific medical interventions even in the absence of clear evidence, because it is 
perceived as easier and associated with less psychological burden than adequate 
advance care planning including an honest weighing of the options. Typical 
interventions that are often questionable include serial operations for tumors that 
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cannot be controlled surgically, repeat irradiation that is often combined with 
immunosuppressive steroids, or “salvage” chemotherapies beyond one or two 
alkylators for patients with gliomas, e.g., platinum-based regimens or irinotecan. 
These are just a few important measures commonly encountered in clinical practice 
for which no supportive data from controlled trials exist. It is only now that many of us 
realize that we occasionally treat where we should not. Further, we should prudently 
weigh risk and benefit of systemic pharmacotherapy in all disease areas where there 
is little or no evidence for pharmacotherapy at all, not only in meningioma or 
ependymoma in adults, but also in recurrent glioblastoma where no intervention 
except nitrosoureas in patients with tumors with O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation is likely to confer meaningful 
disease control. The attitude towards too generous corticosteroid prescriptions has 
already changed in recent years, but the time has come now to verify the need for 
steroid medication in every patient, notably also during radiotherapy where these 
agents are still occasionally given by default. On the other hand, treatments with 
clear benefits such as combined radiochemotherapy in MGMT promoter-methylated 
newly diagnosed glioblastoma should not be withheld from patients by default. This 
applies also to highly immunosuppressive treatments such as high-dose 
chemotherapy in primary central nervous system lymphoma. 
 
Specific COVID-19 pandemic-related recommendations 
There are also disease-specific considerations where the risk benefit ratio has 
changed. It is common practice to scan brain tumor patients in regular intervals even 
after years of stable disease without intervention. During the COVID-19 pandemic, 
we should explore whether we may delay repeat scanning and outpatient visits in 
patients in stable conditions who are asymptomatic. Radiotherapy schedules can 
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probably be adapted to hypofractionation in defined patient populations, e.g., patients 
with brain metastases or MGMT promoter-unmethylated glioblastoma, without 
compromising outcome, but with a major reduction in hospital visits. For systemic 
chemotherapy that is potentially immunosuppressive, including alkylating agent 
chemotherapy, dosing should be conservative and the tresholds for dose reductions 
may need to be lowered to improve safety, notably in diseases where prolonged 
exposure to treatment is probably needed, e.g., lower WHO grade gliomas. 
Nobody would dispute that temozolomide would not have been approved based on 
the data observed in the patient population with glioblastoma lacking MGMT 
promoter methylation (Hegi). Yet, given the doubts on the reliability of assessing the 
MGMT status and the lack of alternative drugs approved in the newly diagnosed 
setting, temozolomide has been maintained as standard of care for all patients 
matching the inclusion criteria of the registration trial (Weller). One might argue that 
the cons currently overrule the pros when evaluating temozolomide for patients with 
MGMT promoter-unmethylated glioblastoma, given the risk of lymphopenia, repeated 
blood tests, and overall more contact with the health care system. Scepticism 
regarding alkylating agent chemotherapy is even more appropriate in the recurrent 
setting where neither temozolomide nor nitrosoureas offer major clinical benefit 
unless the MGMT promoter is methylated. 
 
Access to intermediate and intensive care 
The heated discussion on whether and which oncology patients, suffering from 
COVID-19 or not, should have access to intensive care medicine is an important one, 
but as yet in most countries mainly a preparation for a feared scenario where 
capacities are truly limited and triage becomes important. This cannot be regulated 
by recommendations in ESMO Open or elsewhere, but strongly depends on local 
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circumstances. What is important in the current situation is to indicate in any medical 
report somehow the overall prognosis of each patient to ascertain that those 
colleagues who have to make decisions under stress and time and resource limits 
are adequately informed. Patients with curatively operated tumors, e.g., 
schwannomas or meningiomas, who have no evidence of recurrent disease must not 
be placed in the same category as recurrent glioblastoma patients, but having a brain 
tumor is still often perceived as stigmatizing. 
 
Clinical trials 
Clinical trials deserve specific consideration in the situation of a pandemic as 
experienced now (De Paula). Phase I trials seeking to establish maximum tolerated 
doses with uncertain individual patient benefit need to be viewed with caution unless 
the intervention is highly unlikely to compromise immune function or to cause 
pulmonary toxicity. For most phase II trials, patients already enrolled onto trials and 
being stable may be kept on trial with a careful risk benefit ratio from the patient 
perspective, not from a trial perspective. Essentially the same holds true for phase III 
trials, however, clinical trials evaluating novel treatments that are associated with 
immunosuppression raise ethical concerns: randomizing in the current situation 
against a standard of care indicates that the benefit of the new intervention is 
uncertain, but the perceived risk of increased sensitivity to infection would seem to 
make it prohibitory to place patients on such trials. Particular concern applies to 
placebo-controlled trials in this situation. Resorting to teleconferences and 
videoconsultations and allowing drug shipment to patients include a few measures 
that may maintain trial integrity without placing patients at undue risk. Importantly, 
several companies sponsoring clinical trials have put activities on hold already, and, 
again, many institutions have imposed their own rules on how clinical research is 
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conducted and these regulations obviously overrule any outside recommendations. 
 
Brain tumor patients with COVID-19 infection 
Finally, as time goes by, brain tumor patients who have acquired COVID-19 infection 
will pose new challenges for Neuro-oncologists. For patients symptomatic for COVID-
19 it seems prudent to withhold any systemic chemotherapy, unless entirely non-
immunosuppressive, and to challenge the need for steroids until patients have fully 
recovered from COVID-19. More complicated is the situation of brain tumor patients 
tested for COVID-19 as part of a screen, who come back positive, but are 
asymptomatic for COVID-19. Here, a careful evaluation of risk and benefit is 
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Key considerations for clinical practice 
 
General 
Prioritize transparent communication on risks and benefits of all interventions and 
prioritize advance care planning. 
Challenge the urgency for repeat scanning and outpatient visits in patients in stable 
conditions who are asymptomatic, notably those with less aggressive tumors. 
Avoid the use of treatments, such as reirradiation combined with steroids or 
potentially toxic systemic chemotherapy, for situations where there is no evidence 
for clinically relevant benefit. 
Be absolutely rigorous in controlling the need for steroid prescriptions (“as little as 
possible, as much as needed”). 
Carefully and individually weigh risks and benefits of continued participation for 
brain tumor patients already enrolled onto clinical trials, with consideration of 
national and institutional regulations. 
Advise patients and caregivers to strictly adhere to local measures of limiting the 
spread of COVID-19. 
Specific 
Consider postponing resection or biopsy of non-contrast enhancing primary brain 
tumors with stable neurological symptoms 
Consider hypofractionated radiotherapy in situations where this probably does not 




Weigh benefit versus risk of alkylating agent chemotherapy in patients with gliomas 
lacking MGMT promoter methylation, notably patients with recurrent disease, 
reduced performance status, or in advanced age. 
Consider conservative rather than courageous dosing of chemotherapy notably in 
situations where there is no urgent treatment need and where prolonged treatment 
is likely to provide benefit, e.g., in patients with lower WHO grade 
oligodendroglioma and astrocytoma 
 
 
